openPR Logo
Press release

Rhabdomyosarcoma Therapeutics Analysis 2018 - Clinical Trials, Designations, Collaborations and Developments

09-12-2018 06:13 AM CET | Health & Medicine

Press release from: P&S Intelligence - Pharmaceuticals

Rhabdomyosarcoma Therapeutics Analysis 2018 - Clinical

According to the research findings, most of the drug candidates for the treatment of RMS are being developed to be administered by the intravenous route. The main advantage associated with the intravenous route is that the drug can easily be entered into the bloodstream, or lymph vessels, resulting in high bioavailability of the drug in the body and quick onset of action of drug.

Explore report sample at: https://www.psmarketresearch.com/market-analysis/rms-therapeutics-pipeline-analysis/report-sample

Several companies are developing combination therapies for the treatment of RMS, as these therapies are cost-effective and improve medication compliance by reducing burden of pills. For instance, (Dasatinib + Ganitumab) is a combination therapy under the Phase II stage of development by Bristol-Myers Squibb Company for the treatment of RMS. The drug candidate is a combination of small molecule (dasatinib) and monoclonal antibody (ganitumab), obtained from synthetic and natural source, respectively. It acts as Bcr-abl tyrosine kinase inhibitor and EphA2 receptor antagonist (dasatinib); and insulin-like growth factor-I receptor antagonist (ganitumab).

Most of the companies are developing drug candidates using advanced technologies, and these drug candidates have showed positive efficacy in the clinical stage of development. For instance, Iproteos SL is developing its drug candidate using IPROTech technology platform which involves a combination of in-silico and in-vitro techniques. The technology encompasses state-of-the-art of various scientific fields, such as computational chemistry, modern organic synthesis, peptide chemistry, and experimental validation of potency, absorption, distribution, metabolism, and excretion (ADME) and permeability properties.

Browse report at: https://www.psmarketresearch.com/market-analysis/rms-therapeutics-pipeline-analysis

Some of the key players involved in the development of RMS therapeutics include F. Hoffmann-La Roche Ltd., Epizyme Inc. and Novartis AG.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rhabdomyosarcoma Therapeutics Analysis 2018 - Clinical Trials, Designations, Collaborations and Developments here

News-ID: 1234444 • Views:

More Releases from P&S Intelligence - Pharmaceuticals

Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Download report sample at: http://bit.ly/2eqiPu5 **Various collaborations for CDK inhibitors drug development Eli Lilly
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials and Developments
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development. As per the findings of the research, most of the drug candidates are being developed to be administered by oral route. Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent and Collaborations
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.

All 5 Releases


More Releases for RMS

RF Power Detector Market Report 2018: Segmentation by Type (Non-RMS power detect …
Global RF Power Detector market research report provides company profile for Analog Devices, Maxim Integrated, Texas Instruments, Intersil, Skyworks Solutions, Advanced Microwave, Broadcom, BroadWave Technologies, Clear Microwave and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to
Advancement in Technology to Support the Growth in RMS Therapeutics Pipeline
RMS is a rare and malignant type of tumor which can arise from skeletal muscles, tendons, or connective tissues. The pathophysiology of this type of cancer is still unknown, but when it arises from the skeletal muscles, it can spread to any part of the body. RMS majorly arises from skeletal muscles, but the reason behind this remains unknown. RMS is the most common soft tissue tumor that occurs during
RMS AUTOMOTIVE, MAZDA MOTORS UK FEIERN 10 JAHRE PARTNERSCHAFT
Das langfristige Engagement für das Remarketing von Innovation und Führung setzte einen Meilenstein ATLANTA, 6. Juni 2017 – MS Automotive und Mazda Motors UK stellen die enorme Kraft einer langfristigen Zusammenarbeit unter Beweis und feiern dieses Jahr ihre zehnjährige Partnerschaft voller erfolgs- und leistungsorientierter Ergebnisse. RMS Automotive hat Mazda in dieser Zeit dabei geholfen, mehr als 14.500 Fahrzeuge zu verkaufen und mehr als 75 Prozent des Mazda Händlernetzwerks mithilfe
RMS AUTOMOTIVE & MAZDA MOTORS UK FÊTENT LEURS 10 ANS DE PARTENARIAT
Un anniversaire important marqué par la priorité donnée sur le long terme au remarketing, à l'innovation et au leadership ATLANTA, 6 juin 2017 – Illustrant à merveille la puissance extraordinaire d'une collaboration sur le long terme, RMS Automotive et Mazda Motors UK célèbrent cette année leurs 10 années de coopération, marquées par l'innovation et des résultats dynamisés par les performances.Au cours de cette décennie et grâce à sa solution de
Global EMG Equipment Consumption Market 2017 : Haishen, RMS, Medcom, EGI & SYMTO …
The survey report by Market Research Store is an overview of the global EMG Equipment Consumption market. It covers all the recent trends including key developments in the global market in present and in future. Analyses of the global EMG Equipment Consumption market trends along with the projections of CAGRs (compound annual growth rates) are provided in the research report. Further, an evaluation of the history of the global market and
Retail Realm Announces New Release of Microsoft RMS Utilities Software
Global software distribution company continues to extend retail management functionality. Sonoma, CA (June 13, 2011): Retail Realm (www.rrdisti.com.), a global software development and distribution company, has just released the latest version of their Utility Add-Ons that enhance and extend the industry-leading Microsoft Dynamics Retail Management System (RMS) software. Version 15 of RR RMS Utilities will give retailers the ability to utilize gift loyalty options, configure and send eReceipts, recall